Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Summary
The resale of the Pre-Funded Warrants and the Common Warrants will not be registered.Proceeds from the private placement, along with existing cash and cash equivalents, are expected to be sufficient to fund the Companys planned operations into 2026.The Company intends to use the net proceeds from the Private Placement for general corporate and working capital purposes, including funding clinical trials. Protaras portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). Klinische Einheit, or KE, is a German term indicating a specified weight of dried cells in a vial.Statements contained in this press release regarding matters that are not historical facts are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as predicts, believes, potential, proposed, continue, designed, estimates, anticipates, expects, plans, intends, may, could, might, will, should or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.